Full Text View
Tabular View
Study Results
Related Studies
Third Optimizing Anti-Platelet Therapy in Diabetes MellitUS (OPTIMUS-3)
This study has been completed.
Study NCT00642174   Information provided by Eli Lilly and Company

First Received on March 21, 2008.   Last Updated on February 19, 2010   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Diabetes Mellitus
Coronary Artery Disease
Additional conditions recognized in this trial
Coronary Disease
Diabetes Mellitus, Type 2
Myocardial Ischemia
More general conditions related to this trial
Arterial Occlusive Diseases
Arteriosclerosis
Cardiovascular Diseases
Endocrine System Diseases
Glucose Metabolism Disorders
Heart Diseases
Metabolic Diseases
Vascular Diseases
Interventions listed in this trial
prasugrel
Clopidogrel
Additional drug interventions recognized in this trial
Ticlopidine
More general drug interventions related to this trial
Cardiovascular Agents
Fibrin Modulating Agents
Fibrinolytic Agents
Hematologic Agents
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Pharmacologic Actions
Physiological Effects of Drugs
Platelet Aggregation Inhibitors
Purinergic Agents
Purinergic Antagonists
Purinergic P2 Receptor Antagonists
Purinergic P2Y Receptor Antagonists
Therapeutic Uses
Sponsors listed in this trial
Eli Lilly and Company
Daiichi Sankyo Inc.


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services